Suitable for use to measure free Secukinumab in patient samples.
Recommended antibody pair for pharmacokinetic (PK) bridging assay to measure free drug: CABT-ZB251 - CABT-ZB252
Recommended Working Concentration: 0.005-0.1 μg/ml
Summary
Specifications
Antibody Isotype
IgG1, κ
Clone
33H8
Immunogen
Secukinumab
Conjugate
Unconjugated
Applications
Application Notes
Suitable for use in PK bridging ELISA. We recommend the following for sandwich ELISA (Capture - Detection): CABT-ZB251 - CABT-ZB252 Recommended Working Concentration: 0.005-0.1 μg/ml
General Notes
We recommend the following antibody pair to develop a pharmacokinetic (PK) bridging assay to measure free drug: CABT-ZB251 - CABT-ZB252 CABT-ZB251 is recommended for use as a capture antibody when paired with CABT-ZB252 as a detection antibody. Secukinumab with brand name Cosentyx, is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is marketed by Novartis for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. Secukinumab inhibits a member of the cytokine family, interleukin 17A, which is produced mainly by inflammatory T helper 17 cells. IL17A is upregulated in serum of people with psoriasis and in the synovial fluid of people with psoriatic arthritis, and promotes inflammation when it binds to the interleukin-17 receptor.
Target
Alternative Names
Mouse monoclonal antibody to Secukinumab/Cosentyx; AIN 457; Cosentyx; Secukinumab
Citations
Publication ()
Have you cited CABT-ZB251 in a publication? Let us know and earn a reward for your research.
My Review for Mouse Anti-Secukinumab monoclonal antibody, clone 33H8
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
